TORONTO, March 17, 2017 /CNW/ - GeneNews Limited (TSX:GEN)
("GeneNews" or the "Company") announced today that it has retained
the services of Marcum, LLP, a leading independent public
accounting and advisory services firm in the United States, as its new corporate
auditor, effective March 16,
2017.
In a press release issued on March 7,
2017, GeneNews previously announced that its board of
directors (the "Board") had approved a change of the Company's
auditor and accepted the resignation of Ernst & Young LLP
("EY"). The retention of Marcum, LLP concludes a swift process to
engage a public accounting firm that will fulfill GeneNews'
auditing requirements.
"With its strong reputation and quality of service, Marcum is a
natural fit for GeneNews, and well suited to our size and needs,"
commented James R Howard-Tripp, GeneNews' Chairman & CEO. "With
our new auditor in place, we will continue to maximize our
available financial resources to market GeneNews' comprehensive
portfolio of early cancer diagnostic tests throughout the United States."
The Notice of Change of Auditor, together with the required
letters from Marcum, will be filed on SEDAR.
Notwithstanding the change of auditors, GeneNews anticipates
that the filing of its annual financial statements, management's
discussion and analysis, annual information form and the related
officer certifications for the financial year ended December 31, 2016 will take place on or before
the filing deadline of March 30,
2017.
About GeneNews
GeneNews is committed to becoming a leader in advanced
diagnostics and personalized medicine, serving as a strong
commercialization outlet for early detection of cancer and other
chronic diseases. Our mission is to identify, assess and make
commercially available a comprehensive menu of diagnostics that
provide physicians and patients with personalized clinical
intelligence and actionable information to improve health out-comes
through the early diagnosis of disease. Our Richmond, Virginia-based Innovative
Diagnostics Laboratory clinical reference lab specializes in
traditional and advanced clinical evidence-based blood testing that
helps find, understand, and address cancer risk in patient
populations. Currently, IDL offers risk assessment blood tests for
the three most prevalent cancer types - colon, lung and
prostate. GeneNews' common shares trade on the Toronto Stock
Exchange under the symbol 'GEN'. More information on
GeneNews can be found at www.GeneNews.com.
Forward-Looking Statements
This press release contains forward-looking statements
identified by words such as "expects", "will" and similar
expressions, which reflect the Company's current expectations
regarding future events, including its engagement of a middle
market, U.S.-based independent registered public accounting firm.
The forward-looking statements involve risks and uncertainties that
could cause the Company's actual events to differ materially from
those projected herein. Investors should consult the Company's
ongoing quarterly filings and annual reports for additional
information on risks and uncertainties relating to these
forward-looking statements. The reader is cautioned not to rely on
these forward-looking statements. The Company disclaims any
obligation to update these forward-looking statements, except as
required by law.
SOURCE GeneNews Limited